Life Sciences IP Due Diligence: Implications of Recent Decisions, Legislation, PTO Guidance on Diligence Analysis
Recording of a 90-minute premium CLE video webinar with Q&A
This CLE course will guide counsel for conducting intellectual property due diligence in life sciences deals. The panel will discuss recent court decisions and current and pending legislation relating to patent rights that impact life sciences analyses. The panel will offer steps companies and counsel should take to adapt the due diligence analysis.
Outline
- Recent cases
- Current and pending legislation
- USPTO guidance
- Best practices for life sciences IP due diligence
Benefits
The panel will review these and other relevant issues:
- What are the best approaches for counsel to identify the IP assets to review during due diligence?
- What implications do recent court decisions have on the IP due diligence process in the life sciences?
- How should counsel address IP ownership questions that arise during due diligence?
Faculty
Thomas L. Irving
Partner
Finnegan Henderson Farabow Garrett & Dunner
Mr. Irving has 35 years of experience in the field of IP law. His practice includes due diligence, patent prosecution,... | Read More
Mr. Irving has 35 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. Mr. Irving has served as lead counsel in many patent interferences.
Close
Sherry M. Knowles
Principal
Knowles IP Strategies
Ms. Knowles provides global guidance on complex IP matters, patent litigation strategy and assistance, licensing,... | Read More
Ms. Knowles provides global guidance on complex IP matters, patent litigation strategy and assistance, licensing, patent prosecution, opinions, obtaining and protecting the full value of innovation, investor support and monetization of assets. She is an intellectual property attorney with 30 years of experience in global corporate and private practice. She has acted as an expert witness on licensing matters in several disputes involving large pharmaceutical companies. From 2006-2010, she was the Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, where she served as the worldwide head of patents for all litigation and transactional matters.
Close
Robin Silva
Vice President of IP
Xencor
Ms. Silva is a biotech patent attorney focused on large molecule innovations. Her expertise includes US and foreign... | Read More
Ms. Silva is a biotech patent attorney focused on large molecule innovations. Her expertise includes US and foreign patent prosecution, IP due diligence, counseling, and supporting both biotech litigation as well as technology licensing and collaborations. After almost 30 years as outside counsel, she recently joined her long-term client Xencor as Vice President of Intellectual Property. Xencor is a clinical-stage biopharmaceutical company developing engineered bispecific antibodies and cytokines for the treatment of cancer and autoimmune diseases, and 22 programs incorporating Xencor technologies are in clinical testing, with a plethora of preclinical programs. Xencor partners include, but are not limited to, Janssen, Genentech and Amgen.
Close
Bo Han
Senior Corporate Counsel
Bristol Myers Squibb
Ms. Han is currently Senior Corporate Counsel in the Innovation Law Department at Bristol-Myers Squibb Company (BMS), a... | Read More
Ms. Han is currently Senior Corporate Counsel in the Innovation Law Department at Bristol-Myers Squibb Company (BMS), a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. At BMS, she is part of the Business Development & Commercial IP group, and she handles the full scope of global biopharmaceutical patent issues. She works within collaborative teams to conduct IP due diligence and to advise on IP issues for transactions, including licenses, collaborations, and partnerships. She also protects BMS’s innovations through strategic patent procurement and enforcement of our IP rights through global patent litigation. Prior to joining BMS, she practiced IP law for 8 years at WilmerHale LLP in Boston, MA. She developed expertise in comprehensive global patent strategies and in strategic enforcement of patent rights for biopharmaceutical companies.
Close